Intervention not reported
Severe adverse events: rash · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: rash (moderate certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: pyrexia · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: pyrexia (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: neutropenia · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: neutropenia (high certainty).
1 finding from 1 review
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
OR 0.92 [0.74, 1.13]
9130 participants
Moderate
Intervention not reported
Severe adverse events: raised amylase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised amylase (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised transaminases · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: raised transaminases (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised triglycerides · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised triglycerides (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: central nervous system · antiretroviral‐naïve individuals
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised alkaline phosphatase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised alkaline phosphatase (low certainty).
1 finding from 1 review
Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT) · antiretroviral‐naïve individuals
1 finding from 1 review
Adverse events grade 3 to 5 Range of · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT leads to higher grades III to V adverse events (severe and life threatening, as per… compared with ADT alone (high certainty).
1 finding from 1 review